Universal Health Services (UHS) 2024 Wells Fargo Healthcare Conference summary

Acute care business outlook

• Adjusted admissions grew 3.4% in Q2, with full-year guidance for 3%-4% growth, reflecting a conservative outlook due to strong prior-year comparisons and market recovery pacing differences.

• No material impact detected from the Two-Midnight Rule expansion, attributed to proactive management and third-party consulting.

• Acute care margins are expected to approach pre-COVID levels over the next year or two, though structural challenges like higher physician expenses and outpatient shifts persist.

• Supplemental Medicaid programs, especially in D.C., could add $80-$90 million annually, with approval anticipated late this year or early next year and retroactive benefits.

• Labor costs have stabilized, with premium pay reduced by two-thirds from pandemic highs and wage inflation decelerating; further productivity improvements are expected.

Commercial rates, contracts, and cost structure

• Elevated commercial rate increases secured since mid-2022 will continue to benefit results for another 6-12 months, though some payer pushback is expected as inflation slows.

• Multiyear contract increases negotiated in 2022 will provide ongoing uplift, with the blend of increases stabilizing over time.

• Registry nursing expenses remain above pre-pandemic levels, but further reductions and productivity gains are anticipated as operations normalize.

• Professional fee expenses have stabilized after the No Surprises Act, with the business reset to a new normative expense level and potential for further efficiency.

• AI and technology are being explored to improve demand prediction and staffing efficiency, with ongoing productivity gains across the expense structure.

Expansion, portfolio management, and market dynamics

• New hospitals opening in Las Vegas (late 2024) and Washington, D.C. (spring 2025) are expected to have minimal startup losses due to favorable market dynamics and government support.

• Portfolio management focuses on retaining strong market positions, with potential exits limited to peripheral markets representing the bottom 5% of the portfolio.

• Exchange patient admissions have risen from 4% to 5% of acute care, with reimbursement levels slightly above Medicare but below commercial rates; changes in enrollment are not expected to be material headwinds.

• Medicaid supplemental programs are viewed as durable across political cycles, with reimbursement still below Medicare and some room for expansion in certain states.